Plerixafor for Autologous Hematopoietic Stem Cell Mobilization and Transplantation for Patients in Ontario

A clinical practice guideline for the use of plerixafor for autologous hematopoietic stem cell mobilization and transplantation in patients with hematologic cancers. The guideline examines administration with granulocyte-colony stimulating factor in patients who have or have not been mobilized before. Outcomes of interest include successful apheresis harvest, number of CD34+ cells collected, and survival rate.